Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer

Steen Riisgaard de Blanck; Jonas Scherman Rydhög; Klaus Richter Larsen; Paul Frost Clementsen; Mirjana Josipovic; Marianne Camille Aznar; Per Munck af Rosenschöld; Rasmus Irming Jølck; Lena Specht; Thomas Lars Andresen; Gitte Fredberg Persson

doi:10.1016/j.ctro.2018.07.004

Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer

Steen Riisgaard de Blanck, Jonas Scherman Rydhög, Klaus Richter Larsen, Paul Frost Clementsen, Mirjana Josipovic, Marianne Camille Aznar, Per Munck af Rosenschöld, Rasmus Irming Jølck, Lena Specht, Thomas Lars Andresen, Gitte Fredberg Persson

Research output: Contribution to journal › Article › peer-review

Abstract

Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0–38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.

Original language	English
Pages (from-to)	24-28
Journal	Clinical and Translational Radiation Oncology
Volume	13
DOIs	https://doi.org/10.1016/j.ctro.2018.07.004
Publication status	Published - 2018 Nov
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2018 The Authors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Subject classification (UKÄ)

Radiology and Medical Imaging
Cancer and Oncology

Free keywords

EBUS
Endoscopic ultrasound
Image-guided radiotherapy
Liquid fiducial marker
NSCLC

Access to Document

10.1016/j.ctro.2018.07.004Licence: CC BY-NC-ND

Cite this

de Blanck, S. R., Rydhög, J. S., Larsen, K. R., Clementsen, P. F., Josipovic, M., Aznar, M. C., af Rosenschöld, P. M., Jølck, R. I., Specht, L., Andresen, T. L., & Persson, G. F. (2018). Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer. Clinical and Translational Radiation Oncology, 13, 24-28. https://doi.org/10.1016/j.ctro.2018.07.004

@article{11d4f4c9a26b4a93865261569e35ab8e,

title = "Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer",

abstract = "Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0–38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.",

keywords = "EBUS, Endoscopic ultrasound, Image-guided radiotherapy, Liquid fiducial marker, NSCLC",

author = "\{de Blanck\}, \{Steen Riisgaard\} and Rydh{\"o}g, \{Jonas Scherman\} and Larsen, \{Klaus Richter\} and Clementsen, \{Paul Frost\} and Mirjana Josipovic and Aznar, \{Marianne Camille\} and \{af Rosensch{\"o}ld\}, \{Per Munck\} and J{\o}lck, \{Rasmus Irming\} and Lena Specht and Andresen, \{Thomas Lars\} and Persson, \{Gitte Fredberg\}",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors",

year = "2018",

month = nov,

doi = "10.1016/j.ctro.2018.07.004",

language = "English",

volume = "13",

pages = "24--28",

journal = "Clinical and Translational Radiation Oncology",

issn = "2405-6308",

publisher = "Elsevier",

}

de Blanck, SR, Rydhög, JS, Larsen, KR, Clementsen, PF, Josipovic, M, Aznar, MC, af Rosenschöld, PM, Jølck, RI, Specht, L, Andresen, TL & Persson, GF 2018, 'Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer', Clinical and Translational Radiation Oncology, vol. 13, pp. 24-28. https://doi.org/10.1016/j.ctro.2018.07.004

TY - JOUR

T1 - Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer

AU - de Blanck, Steen Riisgaard

AU - Rydhög, Jonas Scherman

AU - Larsen, Klaus Richter

AU - Clementsen, Paul Frost

AU - Josipovic, Mirjana

AU - Aznar, Marianne Camille

AU - af Rosenschöld, Per Munck

AU - Jølck, Rasmus Irming

AU - Specht, Lena

AU - Andresen, Thomas Lars

AU - Persson, Gitte Fredberg

PY - 2018/11

Y1 - 2018/11

N2 - Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0–38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.

AB - Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0–38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.

KW - EBUS

KW - Endoscopic ultrasound

KW - Image-guided radiotherapy

KW - Liquid fiducial marker

KW - NSCLC

UR - https://www.scopus.com/pages/publications/85069701708

U2 - 10.1016/j.ctro.2018.07.004

DO - 10.1016/j.ctro.2018.07.004

M3 - Article

AN - SCOPUS:85069701708

SN - 2405-6308

VL - 13

SP - 24

EP - 28

JO - Clinical and Translational Radiation Oncology

JF - Clinical and Translational Radiation Oncology

ER -

Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer

Abstract

Bibliographical note

UN SDGs

Subject classification (UKÄ)

Free keywords

Access to Document

Other files and links

Fingerprint

Cite this